Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00397982 · ClinicalTrials.gov registry record · Phase 2

Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma

A Phase 2 study of Recurrent Melanoma and Stage IV Skin Melanoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
17
Enrollment target
2
Study locations

NCT00397982 is a Phase 2 study of Recurrent Melanoma and Stage IV Skin Melanoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 17 participants, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00397982, a Phase 2 study of Recurrent Melanoma and Stage IV Skin Melanoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
17 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial is studying how well giving temsirolimus together with bevacizumab works in treating patients with stage III or stage IV malignant melanoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of malignant melanoma by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.

Conditions Studied

Recurrent Melanoma Stage IV Skin Melanoma Stage IIIB Skin Melanoma Stage IIIC Skin Melanoma

Interventions

  • OTHER Laboratory Biomarker Analysis
  • PROCEDURE Therapeutic Conventional Surgery
  • BIOLOGICAL Bevacizumab
  • DRUG Temsirolimus

Study Locations (2)

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Virginia

  • University of Virginia Cancer Center - Charlottesville

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2008-01
Est. Completion 2013-07
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00397982

The ClinicalTrials.gov registry entry for NCT00397982 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (90% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT00397982 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Virginia.

Frequently Asked Questions

What is clinical trial NCT00397982 about?

NCT00397982 is a clinical study titled "Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma". This phase II trial is studying how well giving temsirolimus together with bevacizumab works in treating patients with stage III or stage IV malignant melanoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Monoclonal antibodies, such as bev...

What is the current status of trial NCT00397982?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2008-01. Estimated completion is 2013-07.

What conditions does trial NCT00397982 study?

This clinical trial studies the following conditions: Recurrent Melanoma, Stage IV Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma.

What interventions are being tested in trial NCT00397982?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE), Bevacizumab (BIOLOGICAL), Temsirolimus (DRUG).

Who is sponsoring clinical trial NCT00397982?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00397982 being conducted?

This trial has 2 study locations across Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Melanoma

All registered trials for this condition

Stage IV Skin Melanoma

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.